[go: up one dir, main page]

MX2021012984A - Anticuerpos y metodos para el tratamiento de la infeccion por influenza a. - Google Patents

Anticuerpos y metodos para el tratamiento de la infeccion por influenza a.

Info

Publication number
MX2021012984A
MX2021012984A MX2021012984A MX2021012984A MX2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A MX 2021012984 A MX2021012984 A MX 2021012984A
Authority
MX
Mexico
Prior art keywords
antibodies
influenza
infection
treatment
methods
Prior art date
Application number
MX2021012984A
Other languages
English (en)
Inventor
Davide Corti
Fabio Benigni
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of MX2021012984A publication Critical patent/MX2021012984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención proporciona anticuerpos que neutralizan la infección del virus de la influenza A. La invención también proporciona ácidos nucleicos que codifican para e inmortalizan células B y células plasmáticas cultivadas que estos anticuerpos. Adicionalmente, la invención proporciona el uso de los anticuerpos de la invención en la profilaxis y tratamiento de la infección por influenza A.
MX2021012984A 2019-04-30 2020-04-30 Anticuerpos y metodos para el tratamiento de la infeccion por influenza a. MX2021012984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/061134 WO2020221450A1 (en) 2019-04-30 2019-04-30 Antibodies and methods for treatment of influenza a infection
PCT/EP2020/062160 WO2020221908A1 (en) 2019-04-30 2020-04-30 Antibodies and methods for treatment of influenza a infection

Publications (1)

Publication Number Publication Date
MX2021012984A true MX2021012984A (es) 2021-12-10

Family

ID=66429359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012984A MX2021012984A (es) 2019-04-30 2020-04-30 Anticuerpos y metodos para el tratamiento de la infeccion por influenza a.

Country Status (17)

Country Link
US (1) US20220226470A1 (es)
EP (1) EP3962530A1 (es)
JP (1) JP7719725B2 (es)
KR (1) KR20220003000A (es)
CN (2) CN114269381A (es)
AU (1) AU2020265407B2 (es)
BR (1) BR112021018409A2 (es)
CA (1) CA3132536A1 (es)
CL (1) CL2021002807A1 (es)
CO (1) CO2021012583A2 (es)
EA (1) EA202192923A1 (es)
IL (1) IL287423A (es)
MX (1) MX2021012984A (es)
PH (1) PH12021552176A1 (es)
SG (1) SG11202109683TA (es)
TW (1) TW202106707A (es)
WO (2) WO2020221450A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7372925B2 (ja) 2018-01-26 2023-11-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド インフルエンザヘマグルチニンに対するヒト抗体
WO2021041989A1 (en) * 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Compositions and methods for treatment of influenza a infection
EP4259655A1 (en) * 2020-12-08 2023-10-18 VIR Biotechnology, Inc. Antibodies and methods for treatment of influenza a infection
CN112812095A (zh) * 2021-01-29 2021-05-18 成都安满生物医药科技有限公司 一种巴洛沙韦酯中间体的合成方法
JP2025512515A (ja) 2022-04-14 2025-04-17 インビジシールド テクノロジーズ リミテッド インフルエンザ感染症を予防又は治療するための組成物
CN115777944B (zh) * 2023-02-10 2023-05-12 北京衡美金叶营养健康科技有限公司 增强身体防御力的组合物及其制备方法和应用
WO2025024541A2 (en) * 2023-07-24 2025-01-30 University Of Miami Aav-delivered antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
MX2011003855A (es) 2008-10-22 2011-12-16 Inst Research In Biomedicine Metodos para producir anticuerpos a partir de celulas plasmaticas.
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2012065055A2 (en) 2010-11-12 2012-05-18 The Rockefeller University Fusion proteins for hiv therapy
US10233229B2 (en) 2012-12-07 2019-03-19 Pfizer Inc. Engineered monomeric antibody fragments
AU2014329609B2 (en) * 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法

Also Published As

Publication number Publication date
EA202192923A1 (ru) 2022-02-16
WO2020221450A1 (en) 2020-11-05
IL287423A (en) 2021-12-01
PH12021552176A1 (en) 2022-09-12
WO2020221908A1 (en) 2020-11-05
CN119192357A (zh) 2024-12-27
CL2021002807A1 (es) 2022-08-19
TW202106707A (zh) 2021-02-16
AU2020265407A1 (en) 2021-10-07
KR20220003000A (ko) 2022-01-07
AU2020265407B2 (en) 2026-01-08
EP3962530A1 (en) 2022-03-09
SG11202109683TA (en) 2021-11-29
JP2022531556A (ja) 2022-07-07
JP7719725B2 (ja) 2025-08-06
BR112021018409A2 (pt) 2021-11-23
US20220226470A1 (en) 2022-07-21
CA3132536A1 (en) 2020-11-05
CO2021012583A2 (es) 2021-10-20
CN114269381A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
ECSP19009170A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
CL2021002307A1 (es) Uso de virus oncolíticos para el tratamiento del cáncer
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CL2019003393A1 (es) Virus oncolíticos y método.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
CL2023000221A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a